Tapentadol for neuropathic pain: a review of clinical studies

References

• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635. doi:10.1212/01.wnl.0000282763.29778.5918003941
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157:1599–1606. doi:10.1097/j.pain.000000000000049227115670
   PubMed Web of Science ®Google Scholar
• Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 2018;17:456–466. doi:10.1016/S1474-4422(18)30071-129598922
   PubMed Web of Science ®Google Scholar
• Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13:292–307. doi:10.1136/practneurol-2013-00053623592730
   PubMedGoogle Scholar
• Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain. 2004;110:510–511.15690577
   PubMed Web of Science ®Google Scholar
• Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122:289–294. doi:10.1016/j.pain.2006.02.00216540249
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N. The multiple challenges of neuropathic pain. Neurosci Lett. 2018;S0304–40. 10.1016/j.neulet.2018.11.054
   Web of Science ®Google Scholar
• Freynhagen R, Arevalo Parada H, Calderon-Ospina CA, et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin. 2018;7:1–16.
   Google Scholar
• Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87:220–228. doi:10.1212/WNL.000000000000284027306631
   PubMed Web of Science ®Google Scholar
• Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16:191–198. doi:10.1007/s11916-012-0256-022395856
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380–387. doi:10.1016/j.pain.2007.08.01317888574
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196. doi:10.1016/S0140-6736(12)61729-223245607
   PubMed Web of Science ®Google Scholar
• Moriarty O, Ruane N, O’Gorman D, et al. Cognitive impairment in patients with chronic neuropathic or radicular pain: an interaction of pain and age. Front Behav Neurosci. 2017;11:100. doi:10.3389/fnbeh.2017.0024628659771
   PubMed Web of Science ®Google Scholar
• Stocks J, Tang NK, Walsh DA, et al. Bidirectional association between disturbed sleep and neuropathic pain symptoms: a prospective cohort study in post-total joint replacement participants. J Pain Res. 2018;11:1087–1093. doi:10.2147/JPR.S14983029922084
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;162–173. doi:10.1016/S1474-4422(14)70251-025575710
   PubMed Web of Science ®Google Scholar
• Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA. 2018;319:818–819. doi:10.1001/jama.2017.2154729486015
   PubMed Web of Science ®Google Scholar
• Langley PC, Van Litsenberg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in western Europe. J Med Econ. 2013;16:85–95. doi:10.3111/13696998.2012.72954822970839
   PubMedGoogle Scholar
• Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. J Pain Eur. 2018;22:216–241.
   PubMed Web of Science ®Google Scholar
• Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: review of the canadian pain society consensus statement. Can Fam Physician. 2017;63:844–852.29138154
   PubMed Web of Science ®Google Scholar
• Tampin B, Briffa NK, Goucke R, Slater H. Identification of neuropathic pain inpatients with neck/upper limb pain: application of a grading system and screening tools. Pain. 2013;154:2813–2822. doi:10.1016/j.pain.2013.08.01823973362
   PubMed Web of Science ®Google Scholar
• Hasvik E, Haugen AJ, Gjerstad J, Grøvle L. Assessing neuropathic pain in patients with low back-related leg pain: comparing the painDETECT questionnaire with the 2016 NeuPSIG grading system. J Pain Eur J Pain. 2018;22:1160–1169. doi:10.1002/ejp.1204
   PubMed Web of Science ®Google Scholar
• Chiò A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017;16:144–157. doi:10.1016/S1474-4422(16)30358-127964824
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in Parkinson’s disease. Mov Disord. 2010;25:S98–S103. doi:10.1002/mds.v25.1s20187254
   PubMed Web of Science ®Google Scholar
• Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics,and therapy. J Neurol. 2017;264:758–769. doi:10.1007/s00415-017-8426-y28243753
   PubMed Web of Science ®Google Scholar
• Scherder EJ, Plooij B. Assessment and management of pain, with particular emphasis on central neuropathic pain, in moderate to severe dementia. Drugs Aging. 2012;29:701–706. doi:10.1007/s40266-012-0001-823018606
   PubMed Web of Science ®Google Scholar
• Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69:13–21. doi:10.1002/ana.2235121280072
   PubMed Web of Science ®Google Scholar
• Kurien T, Arendt-Nielsen L, Petersen KK, et al. Preoperative neuropathic pain like symptoms and central pain mechanisms in knee osteoarthritis predicts poor outcome 6 months after total knee replacement surgery. J Pain. 2018;19(11):1329–1341.
   Web of Science ®Google Scholar
• Thakur M, Dickenson AH, Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nat Rev Rheumatol. 2014;10:374–380. doi:10.1038/nrrheum.2014.4724686507
   PubMed Web of Science ®Google Scholar
• French HP, Smart KM, Doyle F. Prevalence of neuropathic pain in knee or hip osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;47:1–8. doi:10.1016/j.semarthrit.2017.02.00828320529
   PubMed Web of Science ®Google Scholar
• Ito S, Kobayashi D, Murasawa A, Narita I, Nakazono K. An analysis of the neuropathic pain components in rheumatoid arthritis patients. Intern Med. 2018;57:479–485. doi:10.2169/internalmedicine.9235-1729225253
   PubMed Web of Science ®Google Scholar
• Sofat N, Harrison A, Russell MD, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. J Pain Res J Pain Res. 2017;10:2437–2449. doi:10.2147/JPR.S14764029066930
   PubMed Web of Science ®Google Scholar
• Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med. 2015;16:1373–1385. doi:10.1111/pme.1280026176791
   PubMed Web of Science ®Google Scholar
• Gok K, Cengiz G, Erol K, Ozgocmen S. Neuropathic pain component in axial spondyloarthritis and the influence on disease burden. J Clin Rheumatol. 2018;24:324–327. doi:10.1097/RHU.000000000000071129708517
   PubMed Web of Science ®Google Scholar
• Moss P, Benson HAE, Will R, Wright A. Patients with knee osteoarthritis who score highly on the PainDETECT questionnaire present with multimodality hyperalgesia, increased pain, and impaired physical function. Clin J Pain. 2018;34:15–21. doi:10.1097/AJP.000000000000050428379872
   PubMed Web of Science ®Google Scholar
• Adewusi JK, Hadjivassiliou M, Vinagre-Aragón A, et al. Peripheral neuropathic pain in idiopathic Parkinson’s disease: prevalence and impact on quality of life; a case controlled study. J Neurol Sci. 2018;392:3–7. doi:10.1016/j.jns.2018.06.02230097149
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Ger Soc. 2009;57:1331–1339. doi:10.1111/j.1532-5415.2009.02376.x
   PubMed Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14:781–783. doi:10.1016/j.ejpain.2010.06.01720659810
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016;20:1513–1518. doi:10.1002/ejp.87527062079
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–276. doi:10.1124/jpet.107.12605217656655
   PubMed Web of Science ®Google Scholar
• Schukro RP, Oehmke MJ, Geroldinger A, Heinze G, Kress H-G, Pramhas S. Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial. Anesthesiology. 2016;124:150–158. doi:10.1097/ALN.000000000000090226517858
   PubMed Web of Science ®Google Scholar
• Chang EJ, Choi EJ, Kim KH. Tapentadol: can it kill two birds with one stone without breaking windows? Korean J Pain. 2016;29(3):153–157. doi:10.3344/kjp.2016.29.3.15327413479
   PubMed Web of Science ®Google Scholar
• Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10:217–221. doi:10.1177/204946371665736327867511
   PubMed Web of Science ®Google Scholar
• Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113:148–156. doi:10.1093/bja/aeu05624713310
   PubMed Web of Science ®Google Scholar
• Bortolotto V, Grilli M. Opiate analgesics as negative modulators of adult hippocampal neurogenesis: potential implications in clinical practice. Front Pharmacol. 2017;8:254. doi:10.3389/fphar.2017.0025428536527
   PubMed Web of Science ®Google Scholar
• Kress HG, Ahlbeck K, Aldington D, et al. Managing chronic pain in elderly patients requires a CHANGE of approach. Curr Med Res Opin. 2014;30:1153–1164. doi:10.1185/03007995.2014.88700524450746
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17:329–343.25054392
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Alon E, Baron R, et al. Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? J Pain Res. 2011;4:203–210. doi:10.2147/JPR.S1962521887117
   PubMedGoogle Scholar
• Steigerwald I, Müller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28:911–936. doi:10.1185/03007995.2012.67925422443293
   PubMed Web of Science ®Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017;17:678–700. doi:10.1111/papr.1251527611642
   PubMed Web of Science ®Google Scholar
• Horgas AL. Pain management in older adults. Nurs Clin North Am. 2017;52:e1–e7. doi:10.1016/j.cnur.2017.08.00129080585
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30:489–505.
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11:1787–1804. doi:10.1517/14656566.2010.52610620578811
   PubMed Web of Science ®Google Scholar
• Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in japanese and korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013;29:1399–1409. doi:10.1185/03007995.2013.84056823937387
   PubMed Web of Science ®Google Scholar
• Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig. 2014;34:501–511. doi:10.1007/s40261-014-0204-3
   PubMed Web of Science ®Google Scholar
• England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363:2151–2161. doi:10.1016/S0140-6736(04)16508-215220040
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;853S:S3–S14. doi:10.4065/mcp.2009.0649
   Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–162. doi:10.1185/03007995.2010.53758921162697
   PubMed Web of Science ®Google Scholar
• Tominaga Y, Koga H, Uchida N, et al. Methodological issues in conducting pilot trials in chronic pain as randomized, double-blind, placebo-controlled studies. Drug Res (Stuttg). 2016;66:363–370. doi:10.1055/s-0042-10766927224908
   PubMed Web of Science ®Google Scholar
• Vinik A, Shapiro D, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37:2302–2309. doi:10.2337/dc13-229124848284
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35:95–108. doi:10.1007/s40261-014-0249-3
   PubMed Web of Science ®Google Scholar
• Tedeschi A, De Bellis A, Francia PG, et al. Tapentadol prolonged pelease reduces the severe chronic ischaemic pain and improves the quality of life in patients with type 2 diabetes. J Diabetes Res. 2018;2018:1081792. doi:10.1155/2018/108179229675431
   PubMed Web of Science ®Google Scholar
• Galiè E, Villani V, Terrenato I, Pace A. Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci. 2017;38:1747–1752. doi:10.1007/s10072-017-3035-128699105
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7:1581–1595. doi:10.1586/14737175.7.11.158117997705
   PubMedGoogle Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354.12441828
   PubMed Web of Science ®Google Scholar
• Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016;5:F1000. doi:10.12688/f1000research
   Google Scholar
• Dougherty PM. Is chemotherapy-induced peripheral neuropathy more than just a peripheral nervous system disorder? Anesthesiology. 2016;124:992–993. doi:10.1097/ALN.000000000000108526978409
   PubMed Web of Science ®Google Scholar
• Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015;6:432–444. doi:10.4239/wjd.v6.i3.43225897354
   PubMed Web of Science ®Google Scholar
• Simón-Arceo K, González-Trujano ME, Coffeen U, et al. Neuropathic and inflammatory antinociceptive effects and electrocortical changes produced by Salvia divinorum in rats. J Ethnopharmacol. 2017;206:115–124. doi:10.1016/j.jep.2017.05.01628502907
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S. Central nervous system involvement in diabetic neuropathy. Curr Diab Rep. 2011;11:310–322. doi:10.1007/s11892-011-0205-z21667355
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014;8:143–151. doi:10.1097/SPC.000000000000005524752199
   PubMed Web of Science ®Google Scholar
• Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics. 2015;3:152–169. doi:10.3390/toxics302015229056655
   PubMed Web of Science ®Google Scholar
• O’Brien T, Christrup LL, Drewes AM, et al. European pain federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21:3–19. doi:10.1002/ejp.97027991730
   PubMed Web of Science ®Google Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–1765. doi:10.1212/WNL.0b013e3182166ebe21482920
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313. doi:10.1111/j.1533-2500.2008.00204.x18503626
   PubMedGoogle Scholar
• Kern KU, Schwickert-Nieswandt M. Post-zoster-neuralgie des linken trigeminusastes V1 [Postherpetic neuralgia of the left trigeminus nerve V1: successful therapy with capsaicin 8% patch]. Schmerz. 2018;32:464–467. doi:10.1007/s00482-018-0333-330306307
   PubMed Web of Science ®Google Scholar
• Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: national health and nutrition examination survey 2001-2004. Diabetes Care. 2011;34:1642–1647. doi:10.2337/dc10-215021593304
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache R. 2009;13:185–190. doi:10.1007/s11916-009-0032-y
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911–1920. doi:10.1185/030079906X13248817022849
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis JE, Gao J. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2014;15:4–15. doi:10.1111/pme.1222924118776
   PubMed Web of Science ®Google Scholar
• Liu R, Kurihara C, Tsai HT, et al. Classification and treatment of chronic neck pain: a longitudinal cohort study. Reg Anesth Pain Med. 2017;42:52–61; #. doi:10.1097/AAP.000000000000050527846187
   PubMed Web of Science ®Google Scholar
• Baron R, Kern U, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and Tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized phase 3b study. Pain Pract. 2015;15:471–486. doi:10.1111/papr.1219924750558
   PubMed Web of Science ®Google Scholar
• Passavanti MB, Fiore M, Sansone P, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017;17:171. doi:10.1186/s12871-017-0461-929258432
   PubMed Web of Science ®Google Scholar
• Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract. 2016;16:600–609. doi:10.1111/papr.1236126554630
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Mueller-Schwefe GH. Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J Pain Res. 2016;9:1001–1020. doi:10.2147/JPR.S11241827881925
   PubMed Web of Science ®Google Scholar
• Duarte GS, Santos J, Costa J. Response to the publication by Ueberall and Mueller-Schwefe. J Pain Res. 2017;10:1055–1058. doi:10.2147/JPR.S13561928503073
   PubMed Web of Science ®Google Scholar
• Baron R, Kennes LN, Elling C. Retrospective analyses versus RCTs: comparing like with like? J Pain Res. 2017;10:783–786. doi:10.2147/JPR.S13336928435315
   PubMed Web of Science ®Google Scholar
• Billeci D, Coluzzi F. Tapentadol extended release for the management of chronic neck pain. J Pain Res. 2017;10:495–505. doi:10.2147/JPR.S12905628280384
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Kurata J, Sekiguchi M, Yoshida K, Nikaido T, Konno S-I. Attenuation of cortical activity triggering descending pain inhibition in chronic low back pain patients: a functional magnetic resonance imaging study. J Anesth. 2017;31:523–530. doi:10.1007/s00540-017-2343-128365848
   PubMed Web of Science ®Google Scholar
• Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study. Arthritis Rheum. 2013;65:1494–1503. doi:10.1002/art.3792023460087
   PubMed Web of Science ®Google Scholar
• Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111:105–111. doi:10.1093/bja/aet20823794652
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Raffa RB, Pergolizzi J, et al. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015;8:229–238. doi:10.2147/JPR.S8349026064064
   PubMed Web of Science ®Google Scholar
• Brunetti GA, Palumbo G, Morano GS, et al. Tapentadol PR for pain syndromes in real life patients with hematological malignancy. Cardiovasc Hematol Agents Med Chem. 2016;14:68–74.27048320
   PubMedGoogle Scholar
• Nobile-Orazio E. Neuropathy and monoclonal gammopathy In: Said G, Krarup C, editors. Handbook of Clinical Neurology. Vol. 115 (3rd series); Peripheral nerve disease. Amsterdam: Elsevier; 2013;443–459.
   Google Scholar
• Chai E, Horton JR. Managing pain in the elderly population: pearls and pitfalls. Curr Pain Headache Rep. 2010;14:409–417. doi:10.1007/s11916-010-0148-020878270
   PubMed Web of Science ®Google Scholar
• Freo U. Opiates and Cognitive Performances in the Fragile Patient. Venice: XII Neuromodulation Meeting Abstract Book; 2018.
   Google Scholar
• de Tommaso M, Arendt-Nielsen L, Defrin R, et al. Pain in neurodegenerative disease: current knowledge and future perspectives. Behav Neurol. 2016;2016:7576292.27313396
   PubMed Web of Science ®Google Scholar
• Lin CH, Wu RM, Chang HY, et al. Preceding pain symptoms and Parkinson’s disease: a nationwide populationbased cohort study. Eur J Neurol. 2013;20:1398e404. doi:10.1111/ene.1219723679105
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain. 2009;141:14–18. doi:10.1016/j.pain.2008.04.02619062167
   PubMed Web of Science ®Google Scholar
• Freo U, Furnari M, Ori C. Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease. J Pain Res. 2018;11:1849–1856. doi:10.2147/JPR.S16493930271190
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’. Adv Ther. 2018;35:1471–1484. doi:10.1007/s12325-018-0778-x30206823
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opin Drug Discov. 2018;13:965–972. doi:10.1080/17460441.2018.151153930175624
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Kataoka T, Tasaki Y, et al. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan. Jpn J Clin Oncol. 2018;48(4):362–366.29506199
   PubMed Web of Science ®Google Scholar